New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:16 EDTAGN, AERIAerie Pharmaceuticals won't be hurt by Allergan move, says RBC Capital
After Allergan (AGN) said it plans to initiate a Phase III trial for its long-acting prostaglandin glaucoma treatment, RBC Capital does not expect Allergan's move to hurt Aerie (AERI), as Aerie's Roclatan has demonstrated statistically significant superiority to a prostaglandin, according to the firm. Moreover, RBC believes that the glaucoma market is large enough to enable multiple products to succeed. It recommends buying Aerie's stock at current levels.
News For AERI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 15, 2015
10:29 EDTAGNAmerican Urological Association to hold an annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use